Two research teams have developed new noninvasive tests that use either blood or saliva samples to diagnose cases of colorectal cancer or prostate cancer, respectively. Presented today at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, these tests could facilitate screening efforts for colorectal cancer and allow clinicians to better distinguish early-stage prostate cancer from more benign prostate conditions.
As Prostate Cancer Awareness Month comes to a close, researchers want to circulate the message that some gene mutations linked to breast and ovarian cancer are also associated with prostate cancer.
Scientists have identified two subtypes of metastatic prostate cancer that respond differently to treatment, information that could one day guide physicians in treating patients with the therapies best suited to their disease.
New findings by researchers at Yale Cancer Center show the drug combination of nivolumab and rucaparib shows clinical activity for patients with chemotherapy-naïve, metastatic castration resistant prostate cancer.
A paper detailing the method that led to the US Food and Drug Administration approval for PSMA PET imaging, which was led by UCLA and UCSF and their nuclear medicine teams, was recently published in JAMA Oncology.
For men with “low-risk” prostate cancer initially managed with active surveillance, cancer-related factors such as tumor grade and size are key risk factors for conversion to active treatment, reports a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
Over the last decade, advancements have been made in the diagnosis and treatment of prostate cancer that are saving more lives. Tina Mayer, MD, a medical oncologist in the Prostate Cancer Program at Rutgers Cancer Institute of New Jersey shares some insight.
Tina Mayer, MD, medical oncologist in the Prostate Cancer Program at Rutgers Cancer Institute of New Jersey and an associate professor of medicine at Rutgers Robert Wood Johnson Medical School, shares information about prostate health.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts.
Physicians and scientists from UCLA will be joining thousands of urology experts on Sept. 10 to Sept. 13 for the virtual American Urological Association (AUA) Annual Meeting.
Nearly half of men initially managed with active surveillance for “low-risk” prostate cancer transition to definitive treatment – such as surgery or radiation therapy – within a few years after diagnosis, reports a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA).
The Intermediate Clinical Endpoints of Cancer of the Prostate (ICECaP) working group, led by Dana-Farber Cancer Institute researchers, is being honored by the American Statistical Association (ASA) with the 2021 Statistical Partnerships Among Academe, Industry, and Government (SPAIG) Award.
Researchers led by the University of Michigan Rogel Cancer Center identified an inhibitor that showed promise against metastatic castration-resistant prostate cancer cells.
A new, University of Michigan-led study analyzing data from more than 850 patients across the state of Michigan found a commercially available genomic test known as Decipher Biopsy may help identify patients who are at high risk of prostate cancer progression.
New York, NY (July 23, 2021) — Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery , a…
Cardiovascular disease and cancer, the nation’s top two killers, share common ground like obesity and chronic inflammation, as well as a disproportionate impact on Black Americans. A new American Heart Association-funded center at the Medical College of Georgia is working…
What The Study Did: This study included 647 patients with untreated nonmetastatic prostate cancer (269 patients during the pandemic and 378 from before the pandemic). During the initial COVID-19 lockdown, only 1% of Black men underwent prostatectomy, while 26% of…
Most countries have not introduced nationwide prostate-cancer screening, as current methods result in overdiagnoses and excessive and unnecessary biopsies. A new study by researchers at Karolinska Institutet in Sweden, which is published in The New England Journal of Medicine ,…
#ASTRO21 will be the first major medical conference in the city; a curated digital program also will be offered for remote attendees
Miniature 3D bone-like tissue models show effects of anti-androgens
Artificial intelligence-powered diagnostic tool spots asymptomatic prostate cancer in seconds
New ‘nomogram’ opens the door to improved personalized treatments, UCLA-led study shows
Men with high-risk prostate cancer with at least one additional aggressive feature have the best outcomes when treated with multiple healthcare disciplines, known as multimodality care, according to a UCLA study.
Robotic prostate surgery pioneer Mani Menon, MD, is joining Mount Sinai and will serve as Chief of Strategy and Innovation in the Department of Urology for the Mount Sinai Health System. He will also serve as a Professor of Urology, Director of Education and Director of the Precision Prostatectomy Program in the Department of Urology at Icahn Mount Sinai and Center of Excellence for Prostate Cancer at The Tisch Cancer Institute.
FINDINGS Men with high-risk prostate cancer with at least one additional aggressive feature have the best outcomes when treated with multiple healthcare disciplines, known as multimodality care, according to a UCLA study led by Dr. Amar Kishan, assistant professor of…
The article by Dr. Biswa Mohan Sahoo et al. is published in Anti-Cancer Agents in Medicinal Chemistry, 2021
Black men most likely to benefit from advanced prostate cancer therapies are 11 percent less likely to get them than non-Black men. This happens despite apparent equal opportunities in obtaining health care services, a new study in American veterans shows.
Researchers report that about a quarter of localized prostate cancers may demonstrate immunologic traits that suggest a substantial number of patients with prostate cancer may benefit from immunotherapies.
Boston – In recent years, cancer immunotherapy has been effective in treating patients with immunogenic, or so-called “hot” tumors with increased levels of inflammation and the presence of immune cells in and around the tumors. Prostate cancer, however, is considered…
In a new study, a team of researchers uncovered new mechanisms underlying an important type of resistance to modern prostate cancer drugs called lineage plasticity, where castration-resistant prostate cancers undergo a deadly identity switch. They also outline a promising path to overcoming this form of resistance: BET bromodomain inhibitors.
Newly FDA-approved imaging agent now available for patients
An INRS team is investigating the relationship between body mass and the risk of developing cancer
Research from the University of Georgia has identified a protein that appears to prevent the cancer from spreading to and colonizing the bone, providing a new target for future therapeutics.
Researchers identified the protein responsible for cancer’s aggressiveness
New Brunswick, N.J., June 7, 2021 – June is a special time of year focused on heightening the awareness of preventable health problems and encouraging early detection and treatment of disease for men. Diseases like prostate cancer, which is the…
‘Hepatocellular carcinoma (HCC) is the third leading cause of cancer related death worldwide, with a poor median survival time after diagnosis of six months’
MEDIA ADVISORY Senior Author: Ash Tewari, MBBS, MCh, Professor and System Chairman of the Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai and Director of the Center of Excellence for Prostate Cancer…
In a large, international retrospective study, men at high risk for death from prostate cancer had a significant reduction in all-cause mortality if treated with radiation shortly after surgery
New data from researchers at Memorial Sloan Kettering Cancer Center (MSK) featured in the 2021 ASCO Annual Meeting press program highlights a promising new treatment option for individuals previously treated for metastatic castration-resistant prostate cancer (mCRPC).
The impact of deploying Artificial Intelligence (AI) for radiation cancer therapy in a real-world clinical setting has been tested by Princess Margaret researchers in a unique study involving physicians and their patients.
Lung cancer is the leading cause of cancer-related deaths across the globe with more than 1.7 million deaths annually’
‘Head and neck squamous cell carcinomas (HNSCC) are heterogeneous tumors that arise in the upper respiratory tract and are the 6th most common cancer worldwide by incidence’
Some men reach the risk threshold to start screening up to 11 years sooner than guidelines recommend
“SWOG always brings an impressive portfolio of work to the ASCO annual meeting,” said SWOG Chair Charles D. Blanke, MD, “and this year I’m particularly excited about the research our investigators are presenting because it includes results that are likely…
CLEVELAND: According to new findings published in Science Translational Medicine, Cleveland Clinic researchers have identified a promising drug target for treating and preventing aggressive, drug-resistant prostate cancer.
The team, led by Nima Sharifi, M.D., of Cleveland Clinic’s Lerner Research Institute, demonstrated that inhibiting the protein H6PD led to significantly reduced tumor sizes and improved survival among mouse models with drug-resistant prostate cancer. The H6PD levels also were elevated in biopsied patient tumors, suggesting the protein might be targeted in patients for treatment.
University Hospitals offers a new technique called PrecisionPoint Transperineal Access System for obtaining a prostate biopsy. The hospital will also conduct a clinical trial to determine if it offers greater benefits than a traditional biopsy.
University of Virginia School of Medicine scientists have developed important new resources that will aid the battle against cancer and advance cutting-edge genomics research. UVA’s Chongzhi Zang, PhD, and his colleagues and students have developed a new computational method to…
Findings published in Science Translational Medicine
Scientists from the University of Bath in the UK explore racemases and propose strategies for finding drugs that target these important enzymes.
Cleveland Clinic cancer researchers are involved with more than 50 studies that’ll be presented at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting, June 4—8, 2021. Key research from Cleveland Clinic focuses on advancements in the prevention and…